I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

On Monday, H.C. Wainwright analyst Ed Arce updated the firm’s stance on Akero Therapeutics (NASDAQ: AKRO), increasing the price target to $75 from the previous $72 while maintaining a Buy rating on ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Yale Catriona, Chief Development Officer at Akero Therapeutics Inc . (NASDAQ: AKRO), recently executed a series of stock transactions involving the company's common stock. On January 27, 2025, ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including ...

SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) Akero Therapeutics snapped a two-day losing streak on Tuesday, jumping 24.72 percent to close at $47.57 apiece as investors gobbled up shares following news ...

SOUTH SAN FRANCISCO, Calif., May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

Finally, UBS Group raised their target price on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research note on Friday, January 31st.

Akero Therapeutics, Inc. has successfully completed its underwritten public offering, selling 6,427,170 shares of common stock at $48.00 per share, including an over-allotment option for an ...